This page contains a Flash digital edition of a book.
Special Feature


NIH Blood Pressure Trial Expands To Include Older Adults Does a lower blood pressure goal cut the risk of heart and kidney diseases, stroke, and cognitive decline?


The National Institutes of Health plans to add about 1,750 participants over the age of 75 to its upcoming Systolic Blood Pressure Intervention Trial (SPRINT) to determine whether a lower blood pressure range in older adults will reduce cardiovascular and kidney diseases, age‐related cognitive decline, and dementia. "No large‐scale clinical trial has examined the impact of aggressively lowering systolic blood pressure among older adults," said Susan B. Shurin, M.D., acting director of the NIH's National Heart, Lung, and Blood Institute (NHLBI).


The American Recovery and Reinvestment Act will fund the first two years of the study expansion — called SPRINT‐Senior — for $12.7 mil‐ lion. The NIH is providing $30.1 million for the remaining six years of the pro‐ ject.


The NHLBI is the lead NIH funder of the study, which is also supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute on Aging (NIA).


"The SPRINT study and the senior 34 EMS PRO Magazine


expansion address four of the 10 com‐ mon causes of death and disability in adults over 75 years: heart disease, stroke, kidney failure, and dementia. The addition of these participants promises to provide useful scientific and public health information on a large and growing segment of the pop‐ ulation," added Shurin.


Current clinical guidelines recom‐ mend maintaining a systolic blood pres‐ sure — the top number in a blood pres‐ sure reading — of less than 140 mil‐ limeters of mercury (mm Hg) for healthy adults of all ages and 130 mm Hg for adults with kidney disease or diabetes. Two previous trials found that reducing systolic blood pressure in older participants reduced stroke, heart failure, and overall cardiovascular events by more than 30 percent. SPRINT will evaluate the safety and potential benefits or risks of maintain‐ ing systolic blood pressure at either less than 140 mm Hg (standard group) or less than 120 mm Hg (treatment group) – a lower target than currently recommended or studied in previous trials.


Announced in 2009, SPRINT is a nine‐ year study to be conducted in over 70 clinical sites across the United States.


Including the 1,750 new SPRINT‐Senior participants, approximately 9,250 peo‐ ple age 55 years or older are expected to be enrolled. Participants will have systolic blood pressure of 130 mm Hg or higher as well as a history of cardio‐ vascular disease; be at high risk for heart disease by having at least one additional risk factor, such as a history of smoking or a high blood cholesterol level; or have chronic kidney disease. Over 40 percent of the SPRINT partici‐ pants are expected to have chronic kid‐ ney disease. SPRINT and SPRINT‐Senior are examples of comparative effective‐ ness research, which compares differ‐ ent interventions or strategies to pre‐ vent, diagnose, treat, and monitor health conditions in clinical settings. SPRINT enrollment will begin this fall. Researchers will treat study partici‐ pants with commonly available medica‐ tions to achieve their target blood pres‐ sure. Those in the treatment group will take an average of three to four med‐ ications. Those in the standard group will take an average of two medica‐ tions. Participants will be seen in clinics every month at the beginning of the study and less frequently as they reach their blood pressure targets. The study will include standard tests for deter‐ mining the health of the heart, kidneys, and brain.


The NINDS and the NIA support SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT‐ MIND), a sub study of SPRINT that focuses on the impact of lowering sys‐ tolic blood pressure on cognitive decline and development of dementia. The study will also include brain imag‐ ing to measure treatment effects on brain structure. SPRINT‐Senior partici‐ pants will also be included in SPRINT‐ MIND.


SPRINT‐Senior will be conducted through the existing SPRINT clinical center networks: • Case Western Reserve University School of Medicine, Cleveland (Principal Investigator: Jackson T.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52